ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc.

NNASDAQ:ADRX
14.00
USD
-0.20
(-1.41%)
Mar 03Next Earn
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Zhen Li
Full Time Employees
100
Sector
Health technology
Industry
Biotechnology
Address
5871 Oberlin Drive, Suite 200 San Diego CA United States 92121
IPO Date
Sep 25, 2026
Website
adarx.com
Business
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Company News

  • ADARx Pharmaceuticals, Inc. (ADRX) Presents at UBS Global Biopharma Conference 2026 Transcript

  • ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

  • ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

  • ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

  • First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks

  • ADARx Pharmaceuticals raises $446.3 million in upsized US IPO

  • ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering